Home / Pharmaceutical company intelligence
PHARMEVO (PVT) LTD. logo
Pharmaceutical company intelligence

PHARMEVO (PVT) LTD.

Private pharmaceutical manufacturer · Karachi · Pakistan

Karachi-based pharmaceutical company founded in 1999, manufacturing and marketing branded generics, nutraceuticals, consumer-health products and medical devices.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date23 Jul 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
PharmEvo (Pvt.) Ltd.
Company type
Private pharmaceutical manufacturer
Address
402, Business Avenue, Block-6, P.E.C.H.S., Shahrah-e-Faisal, Karachi-75400, Pakistan · 75400
Phone
+92 21 34315195-7
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000504 PharmEvo (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000504 185 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx189public portfolio records represented
REG150unique registrations represented
IDX60indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR154current validated price records
G65generic molecules in indexed catalogue
DF8dosage-form groups
TA9therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage81%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage82%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixPHARMEVO (PVT) LTD.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pharmevo-pvt-ltdGenerated 23 Sep 2026Cardiovascular60 · 32%Anti-infectives34 · 18%Endocrine & metabolic25 · 14%Hematology & thrombosis17 · 9%Oncology & immunology16 · 9%CNS & mental health15 · 8%Gastrointestinal & hepatology11 · 6%Other therapeutic areas7 · 4%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioPHARMEVO (PVT) LTD.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pharmevo-pvt-ltdGenerated 23 Sep 2026185presentationsTablet132 · 71%Injection28 · 15%Capsule8 · 4%Infusion8 · 4%Inhalation3 · 2%Suspension3 · 2%Other forms3 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionPHARMEVO (PVT) LTD.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pharmevo-pvt-ltdGenerated 23 Sep 2026152comparable productsBelow peer median46 · 30%Near peer median55 · 36%Above peer median51 · 34%Company median price position+0.9%Lowest-price equivalents23Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsPHARMEVO (PVT) LTD.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pharmevo-pvt-ltdGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,33 shared51% overlapCCL Pharmaceuticals (Pvt.) Limited32 shared49% overlapGetz Pharma (Pvt) Limited30 shared46% overlapMartin Dow Limited30 shared46% overlapScilife Pharma Private Limited29 shared45% overlapGenome Pharmaceuticals (Pvt.) Ltd.28 shared43% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Cardiovascular60 products · 32%
Anti-infectives34 products · 18%
Endocrine & metabolic25 products · 14%
Hematology & thrombosis17 products · 9%
Oncology & immunology16 products · 9%
CNS & mental health15 products · 8%
Gastrointestinal & hepatology11 products · 6%
Respiratory & allergy5 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Angiotensin receptor blockers25 products · 14%
Antidiabetic medicines25 products · 14%
Calcium-channel blockers20 products · 11%
Antineoplastic medicines16 products · 9%
Third-generation cephalosporins16 products · 9%
Fluoroquinolone antibacterials10 products · 5%
Proton pump inhibitors8 products · 4%
Antiplatelet medicines8 products · 4%
Formulation footprint

Dosage forms

Tablet132 products
Injection28 products
Capsule8 products
Infusion8 products
Inhalation3 products
Suspension3 products
Sachet2 products
Solution1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 Arbi-AIrbesartan + Amlodipine 8presentations 100 mg + 10 mg, 100 mg + 5 mg · Tablet #2 BestrixCeftriaxone 6presentations 1000 mg, 250 mg, 500 mg · Injection #3 DapwizDapagliflozin 6presentations 10 mg, 5 mg · Tablet #4 EvocinCiprofloxacin 5presentations 250 mg, 500 mg, 750 mg · Tablet #5 Avsar Plus 160Amlodipine 4presentations 10 mg, 5 mg · Tablet #6 CanlosCanagliflozin 4presentations 100 mg, 300 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median4630% of comparable products
Near market median55within ±5% of median
Above market median5134% of comparable products
Lowest-price equivalents23ties included
Company median price position +0.9% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Innogen N 100 IU/mLHuman insulin (isophane/NPH) · Suspension for injection · 1's PKR 513.37/vial/unit-55.6% vs market median Nuval-D 80 mgHydrochlorothiazide · Tablet · 2 x 7's PKR 26.02/tablet-48.7% vs market median EvoFix 100 mg/5 mLCefixime · Suspension · 60ml PKR 5.85/mL-44.2% vs market median TioCap DPI 18 mcgTiotropium · Inhalation capsule · 3 x 10's PKR 19.52/capsule-40.5% vs market median Letzole 2.5 mgLetrozole · Tablet · 30's PKR 250.67/tablet-38.8% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 33shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 32shared generics Getz Pharma (Pvt) Limited308 products · 63 generics 30shared generics Martin Dow Limited240 products · 63 generics 30shared generics Scilife Pharma Private Limited226 products · 54 generics 29shared generics Genome Pharmaceuticals (Pvt.) Ltd.181 products · 84 generics 28shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers148Distinct registrations among indexed, published, presentation-validated products only
Verified price observations187
Products with a verified price185
Products with multiple price observations2
Source records with multiple versions181
Latest portfolio source check22 Sep 2026
Latest effective price date23 Jul 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

150 unique registration(s) · 60 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaCardiovascular Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Acelar Enalapril 10 mg Tablet 2 x 10's 025495 PKR 148.66 PKR 7.43/tablet Near median
Arbi Irbesartan 150 mg Tablet 1 x 10's 073769 PKR 398.12 PKR 39.81/tablet No comparator
Arbi Irbesartan 300 mg Tablet 1 x 10's 073770 PKR 597.17 PKR 59.72/tablet 15% below median
Arbi-A Irbesartan + Amlodipine 100 mg + 5 mg Tablet 28's 117982 PKR 880.67 PKR 31.45/tablet Near median
Arbi-A Irbesartan + Amlodipine 100 mg + 5 mg Tablet 10's 117982 PKR 321.15 PKR 32.12/tablet Near median
Arbi-A Irbesartan + Amlodipine 100 mg + 5 mg Tablet 14's 117982 PKR 450.27 PKR 32.16/tablet Near median
Arbi-A Irbesartan + Amlodipine 100 mg + 5 mg Tablet 20's 117982 PKR 629.05 PKR 31.45/tablet Near median
Arbi-A Irbesartan + Amlodipine 100 mg + 10 mg Tablet 28's 117983 PKR 1,005.38 PKR 35.91/tablet Near median
Arbi-A Irbesartan + Amlodipine 100 mg + 10 mg Tablet 10's 117983 PKR 366.39 PKR 36.64/tablet Near median
Arbi-A Irbesartan + Amlodipine 100 mg + 10 mg Tablet 14's 117983 PKR 512.07 PKR 36.58/tablet Near median
Arbi-A Irbesartan + Amlodipine 100 mg + 10 mg Tablet 20's 117983 PKR 717.34 PKR 35.87/tablet Near median
Arbi-A 100+10mg Irbesartan + Amlodipine 10 mg + 100 mg Tablet 30's 117983 PKR 1,055.04 PKR 35.17/tablet No comparator
Arbi-A 100+10mg Irbesartan + Amlodipine 100 mg + 10 mg Tablet 7's 117983 PKR 256.03 PKR 36.58/tablet Near median
Arbi-A 100+5mg Irbesartan + Amlodipine 5 mg + 100 mg Tablet 30's 117982 PKR 924.82 PKR 30.83/tablet No comparator
Arbi-A 100+5mg Irbesartan + Amlodipine 100 mg + 5 mg Tablet 7's 117982 PKR 224.03 PKR 32.00/tablet Near median
Arbi-D Irbesartan + Hydrochlorothiazide 300 mg + 12.5 mg Tablet 1 x 10's 073771 PKR 709.64 PKR 70.96/tablet 80% above median
Arbi-D Irbesartan + Hydrochlorothiazide 150 mg + 12.5 mg Tablet 1 x 10's 073772 PKR 480.72 PKR 48.07/tablet 80% above median
Arbi-D Irbesartan + Hydrochlorothiazide 300 mg + 25 mg Tablet 14's 081081 PKR 1,034.70 PKR 73.91/tablet No comparator
Avsar 10/160 Valsartan 160 mg Tablet 4x7's 066841 PKR 1,475.51 PKR 52.70/tablet 12% above median
Avsar 10/160 Valsartan 160 mg Tablet 2 x 7's 066841 PKR 808.18 PKR 57.73/tablet 23% above median
Avsar 5/160 Valsartan 160 mg Tablet 2x14's 055472 PKR 1,257.81 PKR 44.92/tablet 12% below median
Avsar 5/160 Valsartan 160 mg Tablet 1 x 14's 055472 PKR 688.74 PKR 49.20/tablet Near median
Avsar 5/80 Valsartan 80 mg Tablet 2x14's 055471 PKR 878.85 PKR 31.39/tablet 7% above median
Avsar 5/80 Valsartan 80 mg Tablet 1 x 14's 055471 PKR 481.72 PKR 34.41/tablet 24% above median
Avsar Plus 160 Amlodipine 5 mg Tablet 2 x 14's 076357 PKR 527.68 PKR 18.85/tablet 74% above median
Avsar Plus 160 Amlodipine 5 mg Tablet 2 x 14's 076358 PKR 540.39 PKR 19.30/tablet 78% above median
Avsar Plus 160 Amlodipine 10 mg Tablet 2 x 14's 076359 PKR 578.54 PKR 20.66/tablet 21% above median
Avsar Plus 160 Amlodipine 10 mg Tablet 2 x 14's 076362 PKR 572.18 PKR 20.44/tablet 20% above median
Avsar Plus 320 Valsartan 320 mg Tablet 2 x 14's 076360 PKR 890.06 PKR 31.79/tablet No comparator
Diu-Tansin Losartan + Hydrochlorothiazide 50 mg + 12.5 mg Tablet 2x10's 029210 PKR 593.69 PKR 29.68/tablet Near median
Diu-Tansin Losartan + Hydrochlorothiazide 50 mg + 12.5 mg Tablet 1 x 10's 029210 PKR 325.19 PKR 32.52/tablet 5% above median
Myopro Atorvastatin 10 mg Tablet 1x10's Pack 029162 PKR 429.43 PKR 42.94/tablet 55% above median
Myopro Atorvastatin 20 mg Tablet 1x10's Pack 029163 PKR 691.96 PKR 69.20/tablet 48% above median
Myopro Atorvastatin 40 mg Tablet 1x10's Pack 029164 PKR 943.58 PKR 94.36/tablet 25% above median
Nuval Valsartan 80 mg Tablet 2 x 7's 066836 PKR 336.41 PKR 24.03/tablet 27% below median
Nuval Valsartan 160 mg Tablet 2 x 7's 066837 PKR 561.34 PKR 40.10/tablet 21% below median
Nuval-D Hydrochlorothiazide 80 mg Tablet 2 x 7's 066838 PKR 364.28 PKR 26.02/tablet 49% below median
Nuval-D Hydrochlorothiazide 160 mg Tablet 2 x 7's 066840 PKR 617.08 PKR 44.08/tablet No comparator
Ramipace Ramipril 1.25 mg Tablet 2x 14's 029172 PKR 429.94 PKR 15.36/tablet 13% below median
Ramipace Ramipril 2.5 mg Tablet 2x 14's 029173 PKR 727.43 PKR 25.98/tablet 16% below median
Ramipace Ramipril 5 mg Tablet 2 x 14's 034427 PKR 885.81 PKR 31.64/tablet 10% below median
Ramipace Ramipril 10 mg Tablet 2 x 14's 034428 PKR 1,194.35 PKR 42.66/tablet No comparator
Tansin Losartan 50 mg Tablet 2x10's 027195 PKR 592.51 PKR 29.63/tablet 43% above median
Tansin Losartan 50 mg Tablet 1 x 10's 027195 PKR 324.32 PKR 32.43/tablet 56% above median
Tansin DS Losartan 100 mg Tablet 1 x 10's 034425 PKR 432.44 PKR 43.24/tablet 15% above median
Telsarta Telmisartan 40 mg Tablet 1 x 10's 061912 PKR 425.98 PKR 42.60/tablet Near median
Telsarta Telmisartan 80 mg Tablet 1 x 10's 061913 PKR 818.13 PKR 81.81/tablet 9% above median
Telsarta Telmisartan + Hydrochlorothiazide 80 mg + 12.5 mg Tablet 14's 061914 PKR 1,159.54 PKR 82.82/tablet Near median
Telsarta Telmisartan + Hydrochlorothiazide 40 mg + 12.5 mg Tablet 14's 061915 PKR 614.46 PKR 43.89/tablet Near median
Telsarta Telmisartan 20 mg Tablet 10's 061916 PKR 254.79 PKR 25.48/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). PHARMEVO (PVT) LTD — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/pharmevo-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.